Articles tagged with Prostate Cancer
Researchers discovered that FOXA1, a cancer-causing gene, regulates alternative splicing in prostate cancer, influencing disease relapse and patient survival. The study identified specific splice variants linked to cancer recurrence, which could serve as markers for disease relapse and potential drug targets.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
Researchers at UEA discovered that 'normal' prostate cells in men with prostate cancer have specific genetic changes that facilitate the growth and spread of cancer. The study suggests treating the whole prostate, not just affected areas, may be more effective.
African American men are twice as likely to have more aggressive disease compared to non-African American men. Genomic biomarker tests like the Decipher score can identify patients with higher-risk disease, enabling tailored treatment approaches.
A new study reveals that androgen receptor inhibitors can fundamentally rewire prostate tumors, making them more aggressive. The researchers found that most tumors remain fuel-dependent after treatment, but a small percentage convert to double-negative prostate cancer.
The Journal of Nuclear Medicine Technology special issue highlights the potential of theranostics to tailor cancer treatment to individual patients. The innovation uses targeted radiopharmaceuticals for both diagnosis and treatment of tumors.
A new study suggests that neoadjuvant novel hormonal therapy followed by prostatectomy can reduce the risk of recurrent and progressive cancer in high-risk prostate cancer patients. After treatment with NHAs, patients were more likely to have negative margins after surgery and fewer cases of biochemical recurrence.
A randomized phase III trial found that combination hormonal therapy, delivered for a finite treatment interval of 12 months, more durably suppresses PSA levels compared to hormone injections alone. The treatment approach improved disease progression in patients with high-risk biochemically relapsed prostate cancer.
A study from the University of Gothenburg found that the number of surgeries performed by a urology surgeon has no effect on men's risk of developing postoperative urinary incontinence after prostate cancer surgery. The researchers analyzed data from over 4,600 men who underwent robot-assisted radical prostatectomy between 2017 and 2019.
A new study shows that PSMA PET/CT imaging can change treatment plans for nearly 50% of patients with prostate cancer recurrence after radical prostatectomy. The imaging technique detected disease in 46.9% of patients, leading to major changes in treatment plans, including recommendations for additional treatments.
Researchers have identified genetic signatures explaining ethnic differences in prostate cancer severity, particularly in African men. The study found a new prostate cancer taxonomy and cancer drivers that predict life-threatening cancers, providing a critical key to understanding the disease.
A large-scale study by the University of Exeter found that incorporating genetic risk into GP triage processes can improve referrals for those in need, while avoiding unnecessary invasive biopsy investigations for those at low risk. This approach has the potential to significantly impact prostate cancer diagnosis and treatment.
Annual PSA screening associated with reduced risk of prostate cancer-specific mortality among non-Hispanic Black men. The study suggests that annual screening may be particularly important for Black men, reducing their risk compared to less frequent screening.
Men with early prostate cancer are missing opportunities for detection because national guidelines and media health campaigns focus on urinary symptoms despite a lack of scientific evidence. Prostate cancer can be a silent or asymptomatic disease, particularly in its curable stages.
A new study found that over half of adult cancer survivors experience significant hearing problems after chemotherapy treatment. The researchers also discovered that platinum and taxane drugs, commonly used to treat the majority of cancers, are linked to high rates of hearing loss and tinnitus.
The Tango assay combines accumulation and a logical AND gate operation to identify prostate cancer biomarkers in blood samples. It achieves 91% accuracy in detecting prostate cancer in just 15 minutes, offering a non-invasive alternative to biopsies.
Researchers at Umea University have discovered a new function in specific proteins involved in TGF-β signalling pathway, which affects how cancer cells grow and spread. This may lead to easier identification of men at risk of developing aggressive prostate cancer, enabling early treatment.
Researchers have found that high levels of iron can generate toxic free radicals, which damage lipids and ultimately lead to cell death. The team is exploring the use of compounds like JKE-1674 to induce ferroptosis in prostate cancer cells, making them more vulnerable to treatment.
A new study found that men at heightened genetic risk of prostate cancer who adopt healthy lifestyles may see a significant reduction in lethal disease risk. Maintaining a healthy weight, regular physical exercise, and not smoking were key factors associated with a reduced risk.
A Moffitt study shows that adaptive therapy using abiraterone improves patient outcomes and reduces care costs. The approach delays treatment withdrawal to prevent resistant cells from proliferating, leading to longer median time to progression and overall survival.
Researchers have devised a way to deliver carbon monoxide to the body using stable foams that can be delivered to the digestive tract. The foams reduced inflammation of the colon and helped reverse acute liver failure in mice, offering a potential alternative to immunosuppressive treatments.
A study published in the Journal of Clinical Oncology found that biochemical failure is not a reliable surrogate endpoint for overall survival in patients with recurrent prostate cancer. The researchers recommend considering metastasis-free survival (MFS) as the best surrogate endpoint for overall survival in this population.
Researchers at the Netherlands Cancer Institute discovered that prostate cancer cells hijack the circadian rhythm to become resistant to hormone therapy. The study found that proteins regulating the circadian clock play a crucial role in tumor cell survival, offering a potential target for new treatment strategies.
A new study published in Science Translational Medicine reveals that consecutive molecular modifications of the androgen receptor can contribute to drug resistance in prostate cancer. Researchers identified a potential treatment approach using an ACK1 inhibitor to block this resistance.
Current guidelines for salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to consider information from PSMA PET imaging. PSMA PET is effective in identifying recurrences partially or fully outside the clinical target volume, suggesting its value for therapy planning.
A novel targeted radionuclide alpha therapy, AC-NM600, has been shown to achieve significantly better outcomes than its corresponding beta therapy in treating metastatic castration-resistant prostate cancer. The study demonstrated slowed tumor growth and improved overall survival.
A new Loma Linda University study associates high dairy milk intake with a significantly increased risk of prostate cancer. Researchers found no association between non-dairy calcium and prostate cancer risk, suggesting substances other than calcium contribute to the increased risk.
Experts advise against routine prostate cancer tests for asymptomatic men due to the test's limited ability to prevent deaths and potential for overdiagnosis. Instead, they recommend using a 'risk checker' tool to explore options with a doctor, emphasizing the need for evidence-based guidance on PSA testing.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new subtype of prostate cancer that accounts for 30% of all cases. This stem cell-like subtype, characterized by specific gene expression patterns, is the second most prevalent group after androgen-sensitive type.
Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.
A combination of hormone therapy and pelvic lymph node radiation treatment significantly improved survival rates among patients with postoperative prostate cancer, extending their lives by nearly five years. This study published in The Lancet found that nearly 90% of clinical trial patients remained free from progression for five years.
Research found that men taking abiraterone or enzalutamide plus hormone therapy had a higher risk of metabolic and cardiovascular issues than those undergoing hormone therapy alone. This increased risk was observed in patients with Medicare health insurance, who were significantly older than those in clinical trials.
A large-scale study has found that men with prostate cancer have a 50% higher risk of developing serious and potentially fatal blood clots during the five years after their diagnosis. This increased risk is significant because venous thromboembolism (VTE) is a leading cause of death among people with cancer.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
Researchers developed a biosensor using nanostructured and nanoporous surfaces to detect biomarkers in clinical samples, overcoming technical challenges of small sample amounts. The new technology can provide quick and accurate diagnoses for diseases like prostate cancer without needing dilution or preprocessing steps.
New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...
Research suggests that PSA screening can prevent a significant number of prostate cancer deaths, with lower numbers than previously estimated. The study's findings support the benefits of PSA screening, especially for young healthy men and Black men, who have historically been underrepresented in clinical trials.
Researchers identified genetic patterns in brain metastatic prostate cancer cells, revealing potential targets for PARP inhibitor therapy. This study contributes to precision medicine by tailoring treatment to individual patient profiles.
A large population study found that smoking increases the risk of dying from prostate cancer, regardless of tumor stage, and is associated with a poorer prognosis. Smokers have a lower risk of developing prostate cancer but are more likely to be diagnosed at an advanced stage.
A recent study published in BMC Medicine found that obesity is associated with an increased risk of fatal prostate cancer. For every 10cm (four inches) on the waist, the risk of fatal disease increases by 7%. The study analyzed data from over 2.5 million men and found a link between body fat and prostate cancer risk.
Canada's cancer rates are declining overall, but new cases and deaths are on the rise due to an aging population and growing numbers. Despite this, efforts in cancer prevention, screening, early detection, and treatment have led to improved survival rates for those diagnosed with cancer.
The S1216 study showed an unprecedented median OS of 70 months in the control arm, outperforming previous results by 24 months. This extended survival was attributed to additional life-prolonging treatments patients received after completing the trial therapy.
The joint guide provides a framework for establishing theranostic centers globally, focusing on safety protocols and operational procedures. It highlights best practices for radiation protection, storage, administration, and other topics to improve patient care.
Researchers at Cedars-Sinai have developed an AI tool that accurately predicts pancreatic cancer patients based on CT scan images. Lowering blood cholesterol has also been shown to slow the growth of prostate cancer by enhancing immune cell action. Additionally, a new study found that an ultrasound probe plugged into a smartphone can b...
Research from Weill Cornell Medicine found that less prostate cancer screening has reduced overdiagnosis, but increased incidence of high-grade and metastatic disease. The study analyzed over 438,000 men with newly diagnosed prostate cancer between 2010 and 2018.
Researchers at Memorial Sloan Kettering Cancer Center have obtained exquisite views of the androgen receptor using cryo-electron microscopy. The study reveals unique features of the receptor that enable it to turn on a wide range of genes, distinct from other hormone receptors. This newfound understanding provides clues to how androgen...
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
A study suggests that accounting for genetic factors causing normal variations in PSA levels could improve the accuracy of prostate cancer detection. By analyzing data from over 95,000 men, researchers identified a polygenic score that accounted for 7.3-8.7% of variation in baseline PSA levels and was not associated with prostate cancer.
Researchers identified rural Georgia counties with high mortality rates from breast, prostate, colorectal, and lung cancer. These hotspots were concentrated in the eastern Piedmont to southern Coastal Plain regions, as well as southwestern and northern rural areas.
A novel nuclear medicine combination therapy combining <sup> 177 </sup> Lu-PSMA-617 with idronoxil (NOX66) has been shown to be safe and effective in reducing PSA levels by over 50% in men with metastatic prostate cancer. The median overall survival was 19.7 months, suggesting potential for improved patient outcomes.
A study of 51,000 US veterans found a significant decrease in prostate cancer biopsies and diagnoses during the COVID-19 pandemic, with no racial disparity observed. The results suggest that the pandemic may have had a protective effect on prostate cancer diagnosis rates among Black and White veterans.
Researchers at the University of Illinois Chicago are studying licorice-derived substances for their potential to prevent or stop prostate cancer growth. The study suggests that these compounds, such as glycyrrhizin and its derivatives, may have anti-inflammatory and anti-cancer effects.
A novel high-throughput screening assay has been developed to identify inhibitors of the androgen receptor, which plays a critical role in prostate cancer progression. The assay could lead to new treatments for resistant forms of prostate cancer.
Patients with serious illnesses seek cosmetic procedures to maintain their physical and mental well-being, as well as to become comfortable in social settings. The study found that these procedures are often chosen for noninvasive treatments and endorsed by doctors, friends, and family.
A study by MedUni Vienna reveals that mutations in the KMT2C protein lead to increased cell division, driving metastatic prostate cancer. This discovery may enable early diagnosis through a blood test and treatment with MYC inhibitors.
A new radiotracer containing zirconium-89 has significantly improved the accuracy of detecting localizing prostate cancer relapses. The technique allows for earlier treatment using precise radiation therapy, increasing patient survival rates.
Researchers found that adjuvant radiation therapy compared to early salvage therapy reduced mortality risk in men with pN1 prostate cancer. The study, published in the Journal of Clinical Oncology, showed a 8% decrease in mortality for each additional positive pelvic lymph node found at surgery.
A study from Keck Medicine of USC found a significant increase in metastatic prostate cancer cases among men 45 and older, coinciding with the end of routine screenings. The incidence rate rose by 41% in men 45-74 and 43% in men 75 and older.
A novel radioligand therapy has been shown to increase progression-free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients. Ninety-one percent of patients experienced a greater than 50% reduction in PSA values after treatment, with a median PFS of 22 months.
A new study developed an algorithm estimating a person's risk of developing prostate cancer based on age and two prostate cancer markers. The approach was found to reduce the number of false positives by three quarters compared to a standard PSA test while catching the same proportion of cancers, making screening safer and more accurate.